Effect of Transcutaneous Auricular Vagal Nerve Stimulation on Functional Dyspepsia

Overview

Patients with dyspeptic symptoms vary from 10% to 20% globally. Up to 70% of patients with dyspepsia who undergo endoscopy have unremarkable examination and are diagnosed with functional dyspepsia (FD). Given the lack of information related to its pathophysiology, the treatment is largely empirical and of limited efficacy. Previous small study showed therapeutic potential of transcutaneous auricular vagal nerve stimulation (taVNS) for FD. This study aims to investigate whether taVNS can improve the dyspeptic symptoms of patients with FD.

Full Title of Study: “Effect of Transcutaneous Auricular Vagal Nerve Stimulation on Functional Dyspepsia: a Randomized Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: December 28, 2021

Interventions

  • Device: taVNS 10
    • Patients were given taVNS (by Xi’an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s “on” periods and 30s “off” periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)
  • Device: taVNS 25
    • Patients were given taVNS (by Xi’an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s “on” periods and 30s “off” periods; frequency: 25 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)
  • Device: Control
    • Patients were given taVNS (by Xi’an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s “on” periods and 30s “off” periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)

Arms, Groups and Cohorts

  • Experimental: Treatment group 1
    • Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi’an Bashui Health Technology Co., Ltd) at left tragus. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s “on” periods and 30s “off” periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs).
  • Experimental: Treatment group 2
    • Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi’an Bashui Health Technology Co., Ltd) at left tragus. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s “on” periods and 30s “off” periods; frequency: 25 Hz; current intensity: minimal pain threshold; pulse width: 500 μs).
  • Active Comparator: Control group
    • Based on the infection of Hp or not, patients will receive quadruple therapy (amoxicillin, clarithromycin, pantoprazole, and bismuth) or PPI (pantoprazole) plus taVNS (produced by by Xi’an Bashui Health Technology Co., Ltd) at left earlobe. Patients were given taVNS thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s “on” periods and 30s “off” periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs).

Clinical Trial Outcome Measures

Primary Measures

  • Responder rate
    • Time Frame: 4 weeks
    • The proportion of patients whose Functional Dyspepsia Symptom Diary Total Symptom Scores were reduced ≥5 after four weeks treatment when compared with baseline.

Secondary Measures

  • Functional Dyspepsia Symptom Diary (FDSD)
    • Time Frame: 4 weeks
    • The FDSD consists of 5 cardinal items (burning in the stomach, stomach pain, bloating, postprandial fullness, and early satiety) and 3 supplementary items (nausea, burping/belching rating, and burping/belching bother). Each item can be scored from 0 (no) to 10 (worst). Total Symptom Score includes the 5 cardinal items and ranges from 0 to 50.
  • Gastrointestinal Symptom Rating Scale (GSRS)
    • Time Frame: 4 weeks
    • The GSRS contains 15 items. All individual items are scored on a 7-point Likert scale (1 = not at all to 7 = extremely) and are subsequently clustered into five domains (abdominal pain, reflux, indigestion, diarrhea, and constipation); higher scores indicate more severe symptoms.
  • Adequate relief rate
    • Time Frame: 4 weeks
    • The proportion of patients who acquire overall symptom relief when compared with baseline
  • Elimination rate of cardinal symptom
    • Time Frame: 4 weeks
    • The proportion of patients whose cardinal symptom is completely eliminated when compared with baseline.

Participating in This Clinical Trial

Inclusion Criteria

1. 18-65 years old 2. Patients who met the Rome IV diagnostic criteria of FD 3. Moderate to severe FD (functional dyspepsia symptom diary ≥10) 4. Normal upper endoscopy and abdominal ultrasonography within one year. Exclusion Criteria:

1. Injury or inflammation on the ear 2. Asthma or COPD not under control 3. History of cardiac pacemaker planting or other medical digital devices 4. History of VNS treatment 5. Patients with local or systemic diseases which may cause dyspeptic symptoms: Known active peptic ulcer, cholecystitis, gallstone, gastrointestinal obstruction, gastroparesis, and etc.; Known acute or chronic injury of liver or kidney; Obvious hematological abnormality, or endocrine and metabolic diseases; Known malignancy; Obvious cardiovascular or cerebrovascular diseases (such as coronary heart disease, arrhythmia, cerebral infarction and etc.; Other conditions which may be associated with dyspeptic symptoms (such as NSAIDs associated dyspepsia) 6. Patients with serious mental disorders or tendency to suicide 7. Pregnancy or lactic women 8. Inability to give informed consent

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Air Force Military Medical University, China
  • Provider of Information About this Clinical Study
    • Principal Investigator: Yanglin Pan, Associated professor – Air Force Military Medical University, China
  • Overall Contact(s)
    • Yanglin Pan, M.D., 13991811225, yanglinpan@hotmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.